2015 American Transplant Congress
Microvascular Inflammation in Early Protocol Biopsies of Renal Allografts in Cases of Chronic Active Antibody-Mediated Rejection
Aim:Chronic active antibody-mediated rejection (chronic ABMR) is one important cause of late-stage renal allograft loss. However, few reports have used protocol biopsy to observe changes…2015 American Transplant Congress
Pretransplant Antibodies Against Angiotensin II Type 1 Receptor in Renal Transplantation: Preliminary Data from the KNOW-KT Study
BackgroundThe antibodies (Abs) against angiotensin II type 1 receptor (AT1R) have been suggested as a risk factor for graft failure and acute rejection. However, incidence…2015 American Transplant Congress
Quantifying the Survival Benefit of HLA-Incompatible Kidney Transplantation: A Multi-Center Study
Surgery, Hopkins, Baltimore, MD.
A single center study has demonstrated a two-fold survival benefit of incompatible live donor kidney transplant (ILDKT) compared to remaining on dialysis. We sought to…2015 American Transplant Congress
Umbilical Vein Catheter Versus Double J Stent for Ureteric Anastomosis in Renal Transplantation: A Single Centre, Open Label, Randomized Trial
Transplant Surgery, Manchester Royal Infirmary, Manchester, United Kingdom.
Introduction: Double J (DJ) stents are used routinely in renal transplantation to prevent ureteric complications. A recent Cochrane review of literature showed that routine prophylactic…2015 American Transplant Congress
Propensity Score-Weighted Analysis of Induction Therapies in Live Donor Kidney Transplantation in Modern Immunosuppression Era
1Medicine, UTSW, Dallas, TX; 2Clinical Sciences, UTSW, Dallas, TX; 3Surgery, UTSW, Dallas, TX.
Background: Induction therapy with interleukin-2 receptor antagonist (IL2-RA) is recommended as a first line agent in living donor renal transplantation (LRT). However, use of IL2-RA…2015 American Transplant Congress
Final Results from the BENEFIT-EXT Trial: A 7 Year Follow-Up of Belatacept Treated Patients
Background: At 3 and 5yrs post-transplant, BENEFIT-EXT showed a renal function benefit and consistent safety in belatacept (bela) treated pts vs cyclosporine (CsA). Final 7…2015 American Transplant Congress
The C1q-Binding Assays and Clinical Outcomes in Kidney Transplantation
Background: Contradictory conclusions have emerged from clinical trials when testing the predictive value of C1q-binding donor-specific HLA-antibodies (HLA-DSA). The aim of this study was to…2015 American Transplant Congress
Donor and Recipient Pretransplant Polyoma BK Serostatus: Relationship to BK-Viremia After Renal Transplantation
Surgery, Albany Medical College, Albany, NY.
Background:Polyoma virus BK nephropathy is a serious complication after renal transplantation and is associated with a significant risk of graft loss and dysfunction. This study…2015 American Transplant Congress
Patients With Severe and Morbid Obesity Benefit from Deceased Donor Kidney Transplant
More than one in three Americans are obese yet obesity is considered a relative and sometimes absolute contraindication to kidney transplant. Previous studies suggest that…2015 American Transplant Congress
Resolution of Glomerular Fibrin Thrombi in Deceased Donor Kidneys
BackgroundDeceased donor kidneys with Glomerular Fibrin Thrombi (GFT) are frequently discarded, but these kidneys may offer an opportunity to increase deceased donor organs. Our aim…
- « Previous Page
- 1
- …
- 475
- 476
- 477
- 478
- 479
- …
- 531
- Next Page »